Jubilant Ingrevia gets EIR from USFDA for manufacturing facility in Gujarat

27 Jun 2024 Evaluate

Jubilant Ingrevia has received Establishment Inspection report (EIR) from United States Food and Drug Administration (USFDA) with Zero 483 inspectional observations for the inspection performed in the month of April, 2024 at Manufacturing facility, Unit -1 located at Bharuch, Gujarat, India.

This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company’s strategic capex initiative, shall position Jubilant Ingrevia further to capitalize and mark company’s foray into regulated market to cater the growing business requirements in the Nutraceuticals, Dietary Active Ingredients, Cosmetic Grade Applications – Active Ingredients, Drug Intermediates, CDMO products intended for industry application and human consumption. 

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers.


Jubilant Ingrevia Share Price

800.85 -38.30 (-4.56%)
08-Jan-2025 12:05 View Price Chart
Peers
Company Name CMP
Tata Chemicals 1003.45
SRF 2335.00
Pidilite Inds. 2889.00
Aarti Inds 395.65
Atul 6847.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.